Skip to content

Multicenter, Prospective, Randomized Controlled Clinical Study on the Effect of Early Methylene Blue Application on Mortality in Patients with Septic Shock

Multicenter, Prospective, Randomized Controlled Clinical Study on the Effect of Early Methylene Blue Application on Mortality in Patients with Septic Shock

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500112352
Enrollment
Unknown
Registered
2025-11-12
Start date
2025-12-01
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Septic Shock

Interventions

Methylene Blue Group:Drug Preparation: 10 vials of methylene blue injection (2ml, 20mg each) diluted with 5% glucose solution [ref needed?] to a concentration of 2 mg/ml (50ml syringe). Loading Dose:
Control Group:Equal volume of 5% glucose solution. Infusion regimen (loading and maintenance) identical in rate and duration to the intervention group.

Sponsors

Sichuan Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Age >= 18 years; 2.Meet the Sepsis-3 criteria for septic shock: Suspected or confirmed infection; Require norepinephrine to maintain mean arterial pressure (MAP) >= 65 mmHg; Blood lactate > 2 mmol/L despite adequate fluid resuscitation. 3.Within 24 hours of initiating norepinephrine. 4.At screening for enrollment, the equivalent norepinephrine dose exceeds 0.3 µg/kg/min for more than 30 minutes.

Exclusion criteria

Exclusion criteria: 1.Pregnancy or lactation; 2.Severe acute hypoxemic respiratory failure (PaO2/FiO2 20% body surface area); 7.Glucose-6-phosphate dehydrogenase deficiency; 8.Known allergy to methylene blue, phenothiazines, or food colorings; 9.Recent (within 4 weeks) use of serotonergic drugs (e.g., SSRIs, SNRIs, MAO inhibitors); 10.Patient or legal representative refuses consent. 11.Prior use of methylene blue in the current episode of illness.

Design outcomes

Primary

MeasureTime frame
28-day all-cause mortality;

Secondary

MeasureTime frame
ICU survival days within 28 days;Number of days off antihypertensive medications within 28 days;Number of ventilator-free days within 28 days;In-hospital mortality rate;48-hour cumulative fluid balance;Absolute decrease in SOFA score;

Countries

China

Contacts

Public ContactChun Pan

Sichuan Provincial People's Hospital

panchun1982@gmail.com+86 138 1400 9925

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026